Gene Therapies: US FDA Sticks With Bleeding Rate For Hemophilia Approval Endpoint

 
• By Sue Sutter
  
Blood_Test_Vial
US FDA recommends annualized bleeding rate as the primary efficacy endpoint for traditional approval of hemophilia gene therapies. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies